- Home
- OPY vs AUTL Comparison
OPY vs AUTL Comparison
Compare OPY & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPY
- AUTL
- Stock Information
- Founded
- OPY 1881
- AUTL 2014
- Country
- OPY United States
- AUTL United Kingdom
- Employees
- OPY N/A
- AUTL N/A
- Industry
- OPY Investment Bankers/Brokers/Service
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPY Finance
- AUTL Health Care
- Exchange
- OPY Nasdaq
- AUTL Nasdaq
- Market Cap
- OPY 666.7M
- AUTL 609.4M
- IPO Year
- OPY N/A
- AUTL 2018
- Fundamental
- Price
- OPY $63.44
- AUTL $2.21
- Analyst Decision
- OPY
- AUTL Strong Buy
- Analyst Count
- OPY 0
- AUTL 3
- Target Price
- OPY N/A
- AUTL $10.20
- AVG Volume (30 Days)
- OPY 22.5K
- AUTL 1.7M
- Earning Date
- OPY 01-24-2025
- AUTL 11-12-2024
- Dividend Yield
- OPY 1.15%
- AUTL N/A
- EPS Growth
- OPY 83.00
- AUTL N/A
- EPS
- OPY 6.42
- AUTL N/A
- Revenue
- OPY $1,280,442,000.00
- AUTL $10,091,000.00
- Revenue This Year
- OPY N/A
- AUTL $851.83
- Revenue Next Year
- OPY N/A
- AUTL $264.18
- P/E Ratio
- OPY $9.82
- AUTL N/A
- Revenue Growth
- OPY 7.32
- AUTL 82.71
- 52 Week Low
- OPY $36.93
- AUTL $2.07
- 52 Week High
- OPY $70.25
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- OPY 51.98
- AUTL 35.87
- Support Level
- OPY $61.76
- AUTL $2.17
- Resistance Level
- OPY $65.70
- AUTL $2.80
- Average True Range (ATR)
- OPY 1.54
- AUTL 0.17
- MACD
- OPY -0.28
- AUTL 0.02
- Stochastic Oscillator
- OPY 42.52
- AUTL 19.18
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has three segments: private client, asset management, and capital markets. The Private Client segment, commissions and a proportionate amount of fee income earned on assets under management ("AUM"), net interest earnings on client margin loans and cash balances, fees from money market funds, and custodian fees. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.